Piramal Pharma Ltd
NSE:PPLPHARMA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
115.5
293.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Earnings Call Analysis
Q1-2025 Analysis
Piramal Pharma Ltd
Piramal Pharma Limited reported a robust 12% year-on-year revenue growth in Q1 FY '25, driven primarily by an 18% increase in their Contract Development and Manufacturing Organization (CDMO) segment. Additionally, steady double-digit growth in the India Consumer Healthcare sector contributed to this positive performance.
The company's EBITDA grew by 31% year-on-year, achieving an EBITDA margin of 11%, up from 10% in the same quarter last year. This improvement is attributed to ongoing cost optimization strategies, enhanced process efficiencies, superior product mix, and better procurement practices.
Piramal Pharma's net debt-to-EBITDA ratio stands at 2.8x, significantly reduced from 5x a year ago, demonstrating better financial health and enhanced capacity to manage liabilities effectively. The management reaffirmed that internal cash flows are now sufficient to support ongoing investment needs.
The company maintains a commendable quality track record with zero observations from U.S. FDA inspections since 2011. In this quarter, they completed FDA audits at two key facilities without any issues, affirming their commitment to compliance and quality.
Piramal Pharma has integrated sustainability into its core operations, focusing on climate change management, waste and biodiversity conservation, and community enhancement. Their efforts earned recognition as one of India's top sustainable organizations for 2024.
Looking ahead, the company is targeting early teens growth in overall revenue and EBITDA for FY '25, reflecting confidence in their operational strategy and market position. This outlook is built on strong order inflows and recovery signs within the biotechnology sector.
The CDMO division is strategically positioned to capture increased demand tied to recent regulatory changes and supply chain diversification needs. Piramal Pharma has noted an uptick in customer inquiries regarding differentiated offerings, contributing to optimistic growth potential in the sector.
In the complex hospital generics segment, demand for sevoflurane and isoflurane has been strong in both U.S. and emerging markets. However, pricing challenges have been evident, particularly with sevoflurane's pricing pressures noted in the U.S. market.
The India Consumer Healthcare sector reported steady double-digit growth, underpinned by successful new product launches. 'Power Brands' achieved a notable 19% growth, accounting for 48% of total sales and highlighting the brand strength in the consumer sector.
Management confirmed their guidance for FY '25 remains unchanged, expecting early teens growth across all business lines. This strategic conservatism reflects their approach to navigate emerging market dynamics and customer demand fluctuations.
Executive leadership emphasized an ongoing commitment to optimizing operational performance across quarters. The intent is to equilibrate revenue generation to avoid pronounced disparities seen historically in financial reporting.
You don't have any saved screeners yet
Ladies and gentlemen, good day, and welcome to Piramal Pharma Limited Q1 FY '25 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Gagan Borana from Piramal Pharma Limited. Thank you, and over to you.
Thank you. Good evening, everyone. I welcome you all to our post-results earnings conference call to discuss our Q1 FY '25 results.
Our results material have been uploaded on our website, and you may like to download and refer them during our discussion. The discussion today may include some forward-looking statements, and these must be viewed in conjunction with the risks that our business faces.
On the call today, we have with us Mr. Nandini Piramal, Chairperson Piramal Pharma; Mr. Peter DeYoung, CEO of Global Pharma; and Mr. Vivek Valsaraj, CFO of our company.
With that, I would like to hand over to Mr. Nandini Piramal to share her thoughts.
Good day, everyone, and thank you for joining us on our post results earnings call. We have had a good start to the financial year with a steady all around performance. We registered a healthy revenue growth of 12% during the quarter, driven by continued strong momentum in our CDMO business, which delivered 18% year-on-year growth and steady double-digit growth in our India Consumer Healthcare business.
EBITDA for the quarter also grew at 31% year-on-year with an EBITDA margin of 11% versus 10% in quarter 1 FY '24. This is a result of a continuous and ongoing effort towards cost optimization through increased process efficiencies, yield improvements, superior product mix and better product procurement and supply chain strategies.
Our net debt-to-EBITDA ratio continued to be under 3 with 2.8x at the end of this quarter compared to 5x at the end of quarter 1 FY '24 and 2.9x in the previous quarter.
On quality and compliance, we successfully maintained our best-in-class track record of 0 OAI since 2011. This quarter as well, we successfully closed the U.S. FDA inspection at our Lexington facility with an EIR. Also, at our Ahmedabad formulation development facility, we successfully cleared the U.S. FDA audit with 0 observations, thereby becoming the U.S. FDA-approved site for analytical services.
On the sustainability front, we're taking significant strides to integrate sustainability into our operations. We're taking multiple initiatives in the areas of climate change management, water and waste management, conservation of biodiversity, promoting gender diversity, ensuring a safe operating environment, delivering quality products and services and enhancing the quality of life of the communities around us.
Our efforts were recognized as a third addition of the Times Now Global Sustainable Organizations for 2024 where we were honored as 1 of the top sustainable organizations in India.
Moving on to business specific highlights. Our CDMO business delivered yet another quarter of robust year-on-year revenue growth. Over the last 5 quarters, our CDMO business has delivered a healthy growth driven by steady order inflows and strong execution.
Backed by targeted business development efforts, we continue to receive a steady inflow of new orders, primarily for commercial manufacturing of on-patent molecules, which has increased the contribution of innovation-related 50% of our CDMO revenues compared to 35% five years back. Orders for early-stage development continue to come at a gradual pace as well as we await the full recovery in biotech funding.
However, we are seeing some early signs of recovery in biotech funding with an increase in customer inquiries in business, especially for differentiated offerings. We would observe the trend for a few moments before establishing a complete recovery in biotech funding.
Our generic API business also witnessed a pickup in demand during the quarter, led by strong revenue recovery in the CDMO revenues in the recent past, along with continuous efforts towards cost optimization and operational excellence initiatives, we have seen a meaningful improvement in the profitability of the business.
We intend to further take it higher over the medium term to increase capacity utilization and higher contribution from differentiated offerings and innovation-related work. We continue to make calibrated investments in our CDMO business, which are geared towards customer preferences for integrated services, especially in differentiated areas of ADCs, peptides and on-patent API development and manufacturing.
Recent changes in regulations, along with the needs of supply chain diversification are expected to provide medium- to long-term growth opportunities for the CDMO company, and we're preparing to capitalize on the same.
Moving on to our complex hospital generics. We are seeing a strong demand for sevoflurane and isoflurane in the U.S. and emerging markets like Asia, Europe and Rest of World. However, the healthy volume growth was offset by lower price in sevoflurane in the U.S. market.
Our expansion plans are setting up a new manufacturing line sevoflurane in our India facility increasing KSM manufacturing capacity at the site are on track. These are strategic expansions to capture growing demand for sevoflurane increase in our penetration in the rest of world markets. We expect these expansions to operationalize in FY '26.
In the Intrathecal segment, the sales of Gablofen were boosted by onboarding new customers. We continue to maintain a market-leading position in the intrathecal baclofen market in the U.S. with over 70% market share.
In the Injectable Pain Management segment, our growth in the past few quarters was effected by supply constraints at CMO, which is showing some positive traction. We're continuously working towards improving our supplies and thereby strengthening the performance of this business.
Going forward, we're looking to build a pipeline of limited competition, specialty products through investments in R&D and in-house product development capabilities. We'd also be exploring new and licensing deals to bring differentiated products to market and leverage extensive distribution network. These new products will not only help us drive growth in our CHC business but will also help us reduce dependence of sevoflurane.
Moving on to our India Consumer Healthcare business. Our ICH business continues to deliver steady double-digit revenue growth. This is primarily led by new product launches and growth in our power plants. We launched 7 new products and 10 new SKUs during the quarter.
This includes the launch of our brand catering to the Men's Grooming segment. We continue to invest in media trade spend to boost the growth of our power brands. This quarter, we have added geriatric care brand to the list of our brands basis encouraging response received in the first year of this national launch.
Power Brands now includes Little's, Lacto Calamine, Polycrol, Tetmosol and CIR. Our Power Brands grew 19% during the year and contributed 48% of total consumer health care sales.
Our key brands such as Lacto Calamine, Little's and Tetmosol delivered a healthy double-digit growth rate in quarter 1 FY '25, while the growth of the was impacted due to it being brought under price control.
Our sales and e-commerce platforms continue to show formidable growth growing at 37% year-on-year during the quarter and contributing to 19% of the sales versus 15% in quarter 1 FY '24.
Summarizing the performance. I'm very pleased with our overall performance during the quarter and reiterate our FY '25 guidance of early teens year-on-year growth in revenue and absolute EBITDA with a meaningful increase in that.
I'm optimistic about the market opportunities in all 3 lines of business and believe are timely investments in people, capabilities and capacities places us well to capture them. Ongoing efforts towards better profitability, maintaining a best-in-class quality track record and integrating sustainability in our operations continues as we commit to develop our value for all our stakeholders.
With this, I'd like to now open the floor for the Q&A.
[Operator Instructions] We'll take our first question from the line of [ Sajal Kapoor ], a retail investor.
I have 2 questions, please. First, the process of rebalancing the supply chain after COVID has been ongoing. However, has biosecure significantly altered the tone in the innovator boardrooms, I mean, are we witnessing a rise in customer audits and the in the initial order placement for the pilot scale development projects, which kind of logically suggests that innovator are interested in us, but they also need to gain confidence in our capability and hence, they initially only award a small pilot scale development work before awarding the commercial contract. So has any of this been happening in your experience as well? That's my first question.
So thank you for your question. This topic has been top of mind for many of our innovator customers. The issue started to develop at the beginning of the calendar year, and it's becoming much more prominent as the build -- the potential to has progressed through the legislative channels. Just as 1 indicator of interest, we have a customer advisory board, and we had such a meeting in June where we had -- the customers actually asked us 2 weeks before the meeting to change the topic to this topic.
So I would say that based off of our interactions, many of our integrator customers are seriously considering how best to address this potential change in what they can do and how they can do it. Many of them are evaluating options and choices and that often results in inquiries, visits, audits, RFPs, and we are seeing increased activity across this set of dimensions. We have capacity available to support our customers, either in the West or in the East or both depending on their requirements. And we've seen some early modest decisions. But in terms of material decisions, I think they're all still pending at least for the customers that are making choices and evaluating options with us.
That's very helpful, Peter. And my next question is, do you think that the net cash from operating activities over this year and next after adjusting for working capital and debt servicing, although we have been reducing the debt, and there is still a sizable amount of debt on the balance sheet which needs to be serviced through the operating cash flow.
Is this cash this year and next that we'll be generating kind of sufficient to support the growth aspirations of CDMO to capture a fair share of the supply chain rebalancing as well as fund the growth for our complex hospital generics business as well as India consumer business and of course, the ongoing need for additional investment in
So there is a lot of cash requirements across our network globally and the businesses. And the question really is, is our operating cash flow good enough to kind of fund all these aspirations?
So [ Sajal ], thanks for the question. And as you must have seen over a period of time, we have gradually brought down the overall debt on the balance sheet and made it more sustainable. If you look at the debt-to-EBITDA ratio, currently, it stands less than 3.
Our consumer products business actually finds itself. So to that extent, there is no need of any further external funding that we need to put in. Between CDMO and our complex hospital generics business, we should be able to manage thi through our internal accruals. And I think over a period of time, depending upon how needs emerge, we will balance the internal accruals as well as our investments accordingly.
That's helpful, Gagan. If I could sneak 1 last. Piramal Pharma has a unique positioning because we are present globally, so we have got reactors, we've got resources on U.K. soil and as well as in the U.S. and of course, India, do you guys believe that this gives Piramal Pharma an edge or an advantage over some of the Indian companies that are not having presence -- physical presence that is outside outside India? And what I mean by physical presence, I mean development and manufacturing capability, not just the marketing presence?
I do think some of our customers likes to have onshore presence for wherever they are situated because it helps with time zones, they quite often will come to our site to see the product being manufactured or developed. And especially in development, there's a lot of close collaboration with scientists, so they do actually like that onshore.
And I do think the U.S. also gives us an opportunity, for example, to even get work from India. I'll give you an example of a customer we kind of signed a project and they were like, "Okay, we want to sign it, but we can't start for another 6 months because we're waiting on some raw materials because those are late."
And we said, "Well, what are the raw materials? Can we actually make some for you?" And they actually then came to our Digwal facility. And we -- that wouldn't have happened if we hadn't had the U.S. signing, they may not have heard about of our Digwal facility. So that's 1 example.
We have our next question from the line of Abdulkader Puranwala from ICICI Securities.
My first question is on -- basically on the order inflow, what you would have for the CDMO business. Could you provide us some color as to directionally how the movement has been?
[indiscernible] that we -- at this same date this year versus last year, we feel that we're in a meaningfully better position on the full year revenue coverage from POs and revenue booked and high potential in comparison to where we were at the same date last year. And so we feel that, that gives us comfort in the guidance that Nandini mentioned at the beginning of the call.
Sure. Got it. And my next question is on the complex hospital generics business. So when you talk about some price erosion in sevoflurane, could you please quantify the impact? And in terms of the incremental growth -- so is that coming from the U.S. market or that's largely led by the emerging markets in Europe?
I don't think we've quantified the volume price mix of individual products in the CHG, but there was a price reduction from 1 contract in the U.S. that happened in the second half of last year, and that's what's showing up in the first half or the first quarter this year on a rolling basis.
If you look at the volume growth, given that most of the contracts in the U.S. are somewhat stable, while there's some modest movements, most of the volume growth has been ex U.S., which would be a combination of Europe and ROW.
Got it, sir. And 1 final question of the Consumer Health business. So if I look at the presentation, mentioned that the Power Brands has grown at close to 19% and it accounts for 48% of the revenue. So -- which kind of specifies that the growth in the balance of portfolio was subdued. So could you please help us understand what are the efforts taken for boosting growth? And when we talk about the promotional expenses, how evenly is that getting distributed?
So in advertising and promotion, it's pretty much going all to the Power Brands and that's what we expect them to grow -- to continue. The other brands, I'd say are more on sustainable, and that's what we're going to do. That's what going forward as well.
[Operator Instructions] Next question is from the line of [indiscernible].
I have 2 questions. One, I wanted to know what kind of utilization levels are we seeing in the U.S. plant? I believe we were at 40%, 45%? And also employee cost as a percentage of sales, it's at 30% currently. So is that kind of the new run rate going forward?
So firstly, on the capacity utilization, we have a higher level of capacity available in our drug products versus drug substances. And as you're aware, we have done investments to create capacities for all differentiated offerings wherever our capacities were short. It's difficult to give 1 percentage number when you're dealing in different kind of capabilities across formulations, APIs and related capabilities. So in terms [Technical Difficulty].
Sorry, we are not able to hear you. are you online?
Yes. Yes. I just wanted to know, is it directionally...
One moment. Is the management team connected because I'm getting a blank. [Operator Instructions] Ladies and gentlemen, we have the management team back on call.
Sorry, I missed the last part of the answer, but I just -- more than a percentage I was looking for, is it directionally higher than what we were, say, last financial year?
Yes. So for this particular quarter, there is a little bit of unevenness and I wouldn't say that is the indicator of how it will be in subsequent quarters. The guidance that we had given over for the full year was a high-teens growth in our OpEx and that's how it will be. So please don't consider this as a run rate.
And as a percentage of turnover, obviously, because we've got higher revenues coming up in H2, you will see the percentage of the -- staff cost as a percentage of turnover going down subsequently.
We have our next question from the line of Sanjaya Satapathy from Ampersand
Congratulations for starting the year on a good note with the margin expansion. And we heard that your order book would look better this year compared to last year. So considering all this, are you looking to upgrade your guidance that you had given at the beginning of the year?
See, Sanjaya, at this point in time, we maintained the guidance that we had already given. We are not looking for an upgrade right now.
Understood. And is it because you were looking at some kind of execution challenges or any particular...
No, no such thing. Over a period of time, we'll have to see how the year progresses. Currently, of course, we had certain higher front-loading, which happened, but we'll have to see how this evens out over a period of time. So no change in the guidance for now.
And we will also want to balance the quarter...
I'm sorry, ma'am, can I come closer to the phone, please?
We'd also like to balance the quarter so it's not so uneven, and that's something that we're working on.
So how will that be done [indiscernible] are you saying that the 50, 40 -- 55-45 split will change going forward?
I think last year, there was a very -- quarter 4 was much, much bigger. While I don't expect the split to change but as in H1, H2, but I do expect a little more balancing across the quarter.
Understood. And other thing that I just wanted to check on that the CHG business on which you were planning to some onetime expense this year for [indiscernible] in nonregulated market. Was there any such expense this quarter as well? And how is the guidance on that for the rest of the year?
So if I've heard you correctly, you are referring to certain one-off expenses in our complex hospital generics business, which we have spoken in the previous quarter. A very small portion of that has been spent and the remaining should possibly come up in the subsequent quarters.
Understood. Understood. And last thing on the CHG, price increase which you have seen in the last year second half, is there any -- considering that the volumes have started improving, is there any sense that we're getting in terms of price kind of moving back up?
We don't anticipate price to be increasing generally in generics. There may be a few isolated cases of some of our smaller products or there may be some market dislocation, but there may be some possibility that these would be not so large products in our portfolio.
The large products and portfolio, generally prices stay flat or go down given the multiple options available, although they do go down in a more modest rate than other generic categories. So we see this as reasonably stable, and we would see the year-on-year price decline driven by actions that happened last year second half, and we don't see any major changes in the near term.
Next question is from the line of Devang Shah from Enterprise.
My 1 question is simple. Like 3 years back, when this company was with the Piramal Enterprise company was growing very good. After that, we didn't understood what has happened, like we are in the loss also. And as well as the -- you can check out -- like we can check out the debtor days, cash conversion cycle, everything has gone from upside down. So don't understand the thing like what the company is currently doing? And what are the targets?
Is what I like the whole numbers or the other everything which was looking very fancy has been hidden inside the Piramal Enterprise or it's after that like something has gone totally wrong? Like I'm not understanding the thing like currently also a company is not in the net profit.
So if you look at our trend across the years, quarter 1 for us is always the lowest quarter. And if you see, even in the last 4, 5 years, you would have seen that quarter 1, we have actually made a loss because the way our entire deliveries are scheduled, it picks up in quarter 2 and quarter 3 and then peaks towards quarter 4. That's been the historical trend, and you can pick up any year over the last few years, you will see a similar trend.
Talking about the turnaround. As you are aware that during the pandemic period, some of our businesses were impacted, and that was followed by impact on account of the biotech funding crisis and the geopolitical situation. But having said that, in the last year FY '24, if you've seen the numbers, you'd have seen that there has been a meaningful turnaround both in the top line, improvement in EBITDA as well as improvement in the operating margin, reduction in debt and a meaningful reduction in the overall operating expenses and improvement in PAT margin. it's all moving in the right direction.
And as you must have heard in the opening comments from Nandini, quarter 1 has also begun this year on a good note. So we look forward, and we are optimistic about the potential of each of our businesses. and are working towards ensuring that they all move towards their respective path of success.
I think so operating profit margin is 12%. So on 12%, we are expecting like it cannot be -- it cannot move in 1 or 2 years to 20%, right? 14% OPM how can anybody can expect everything will go -- and if the numbers are coming at really very good, right, then how is it possible, like I'm not to understand then the company has to take the debt? You have the cash also on the books, you have the resources also there.
And there is the same -- at the same rate, the liability has also increased. So is the money you are getting it very cheap? So you are just borrowing out there? Or you are just taking up the resource, like you cannot utilize the same funds.
as far as quarter 1 margins are concerned, as I alluded to, quarter 1 is the smallest quarter for us. Therefore, operating margin tends to be the lower year and it progressively increases as our revenue goes up in the future. And with respect to...
Sorry, but quarter 1 margin is 10% OPM. I'm talking for 14%, which is quarter 2 and quarter 3. So at 14% OPM is -- are you thinking that it's a good one?
As we've alluded to, [ Devang ], our intent is obviously to increase our operating margins progressively across the period. And we believe that we have a pathway to be able to accomplish that. And also to respond to your question on debt, our debt has largely been towards doing acquisitions and CapEx, all of which are growth-oriented and they have been done in areas where we believe we have the highest potential for growth.
Is it like can we grow by higher teen numbers, 18% plus OPM within the next year? Is the management confident for that?
[ Devang ], at this point, we are not giving a guidance for the next year. But as we said on the longer term, our intent is to obviously improve and enhance our margins and we've given that indication before as well.
We have our next question from the line of from Ventures.
I just had 1 question regarding our debt. While we understand that the net debt number has reduced significantly, and it's now less than 3. However, the sale is not being reflected in the interest expense line item in the P&L. Could you just share us some guidance on that? When will that line item will reflect a reduced net debt position?
So yes, 2 things happened. So while our overall debt reduced, especially post the rights issue, the interest rates went up. So as you read most of our debt, which is linked to several benchmarks, whether it's the SOFIR or whether it's the LIBOR, all of these rates actually went up anywhere between 9% to 17% in the last 12 months.
And therefore, while the average borrowing is lower, the interest -- increase in interest rates has kind of offset some of the benefits, but we are hopeful that once interest rates start reducing, you will see the benefit of that trickling. If you see the overall interest cost in this quarter as well, will notice that there is a reduction in the interest cost in absolute value.
Okay, understood. Second question was regarding the tax. The tax amount for this quarter seems to be high. So do you expect this to be even out for
That's right, So some of our overseas entities have a meaningfully higher skew of profitability in H2 over H1. The provisioning of tax that you see in this quarter is at the standard rates in profitable entities, whether it's India or U.S. And you will see this balance off progressively as revenues and profitability in our overseas sites start increasing.
Okay, understood. So we can safely assume 50% bracket for the full year, right?
Yes, fairly in line with what we have guided for.
We have a next question from the line of Vinod Jain from WF Advisors.
My question is basically answered. It was related to direct tax. But the long-term view on attrition at 50%, why is it on the higher side if corporate tax rates are lower?
So Mr. Jain, as I alluded to that the tax rate currently appears profitably in some of our overseas entities currently is lower than what it should actually be or they are in the negative right now. As the profitability in these entities increase, you will progressively see a reduction in the effective tax rates. Having said that, in jurisdictions wherever we are profitable, we pay tax at the standard rates.
So the long-term average rate could be around 50%?
No, it will progressively reduce as the profitability increase.
[Operator Instructions] We have a question from the line of Abdulkader Puranwala from ICICI Securities.
Just on the ADC segment. So a couple of quarters back we have highlighted that we have capabilities for this particular segment. Any color as to what level of engagement we are having with clients? And do we see some order commitments also coming up in the near term?
Regarding ADC orders?
Yes.
So we do see significant interest in this segment from clients and potential clients. We have also noticed that we're interested in across what we do in conjugation linker payload finish in Lexington. That said, we have noticed that all our offerings, this is the longer sales cycle for a client to decide with the complexity.
And then once they decide to longer from PO to revenue cycle because of those appointing lead times vis-a-vis the other offices network. So we remain quite confident in the over underlying demand for the segment. We remain excited about the level of customer engagement and potential projects and some recent signings, but the translation firm idea to revenue is longer for this differentiated offering than some of our other ones. So we would say watch this space. We're excited we hope to be able to share in the future with you.
Sure. Got it. Lastly, on the CapEx, what we had planned for complex hospital generics segment, where we plan to add some line at the Dahej and other plants. So I mean, where are we in the capacity expansion? And by when would this added capacity come up?
So we are making substantial progress on that -- those 2 projects that you described and that we communicated earlier. Right now, we would say that it's still on track. We have no reason to believe anything other than it will happen the way we described. And what we had communicated is that we will continue to reaffirm which should be the an FY '26 benefit.
Sure. And finally, on the men's grooming brands what you had acquired, I mean, could you just help us understand what the potential market here is? And can any of those become one of your existing -- or part of your existing Power Brands?
I think it's -- we've launched them, they are on products, they're not acquired. We hope that they can eventually become part of our Power Brands. I think we've launched them on e-commerce only. We will see the response on it. And once it gets to a certain scale, we will take that offline and on to the general trade.
We have our next question from the line of [indiscernible] from Elara Capital.
I just wanted to know the breakup in CDMO segment. So what percentage of revenue might be from the innovative business and what percentage from the development?
So of the innovator business overall, it's 50%, but that includes about -- it includes discovery as well as development as well as on-patent commercial.
Understood. And the second is towards the complex hospital generics. How many products are we planning to launch in FY '25?
So currently, we have 5 of them approved, and there are about 17 in the pipeline in various stages of approval.
So any like expected, like any approvals expected in this year?
Yes, it's difficult to communicate that specifically in terms of how many of them would actually get approved this year.
Understood. Understood. So what will be our guidance towards the Power segment -- sorry, Power Brands for FY '25? How do we target it -- like what do we look by the end of the FY '25 Power Brands contributing to us?
I think we'll think that they will grow [Technical Difficulty] the overall business, but I don't think we want to take a specific number.
We have a next question from the line of [indiscernible] from Fair Value Capital.
So just 2 quick questions. First is if you could...
Mr. sorry, you're audible, but it is not clear. Can you use your handset mode, please?
Just 2 quick questions. First, if you can give the share that new products in your CHG business contribute to revenue?
I think the products would be not -- they would be quite small. Modest.
All right. And if I look at the advertisement spends, earlier they used to be 18% to 20%, but as mentioned in the PPT, it has -- it was 13% for the quarter. So is it because we are focused more on profitability now or -- and therefore, reducing the expense or anything else?
I think the business has grown faster than the market, but we are also focusing on profitable growth.
[Operator Instructions] We have a question from the line of [ Anil Kumar ], an individual investor.
First of all, congratulations on a good set of numbers. We are gradually improving. My 2 questions maybe I missed the initial commentary, the y-o-Y increase in CHG business was just 2% what are the reasons for that? And secondly, we have a joint venture, Allergan, not being that strategic. Do you have any plans to improve that further or to sell it down to reduce some of the debt?
And also thirdly on, I think we have some case going on with antidumping where are we with that?
Okay. So firstly, on the complex hospital generics. While we had seen good volume growth during the period. The average realizations have been lower as we alluded to, and also, we had some difficulty in getting some of the products from our third-party CMOs because of which our growth was subdued during the quarter.
Secondly, with respect to the joint venture, we are very much -- it's now AbbVie Therapeutics India Private Limited. We are very much committed to this JV and believe that it has the potential and prospects to grow further and therefore, actively work to ensure that this JV also is able to scale to its fullest potential.
Sorry, did I miss the third question?
On the antidumping duty application, it's currently under process, and we await outcomes for that. We have done the filing, we are awaiting the outcome.
Ladies and gentlemen, we'll take that as a last question for today. I now hand the conference over to Mr. Gagan Borana for closing comments. Over to you.
Thank you very much. We appreciate you taking the time to join us for today's call. We hope we were able to answer most of your questions. In case any of your questions have remained unanswered, please feel free to reach out to me. Thank you.
Thank you. On behalf of Piramal Pharma Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.